Orthofix reported Q4 2025 net sales of USD 219.9 million (+2.0%), or USD 218.6 million on a non-GAAP pro forma basis excluding M6 disc sales. Q4 2025 net loss was USD 2.2 million, while non-GAAP pro forma adjusted EBITDA was USD 29.2 million (13.4% margin). Q4 free cash flow was USD 16.8 million. For FY 2025, Orthofix posted net sales of USD 822.3 million (+2.9%), with a FY net loss of USD 92.2 million. FY non-GAAP pro forma adjusted EBITDA was USD 85.9 million (10.6% margin). Cash, cash equivalents and restricted cash totaled USD 85.1 million at Dec. 31, 2025. Business highlights included Q4 2025 growth in Global Spine Fixation (+10%), Bone Growth Therapies (+7%), and U.S. Limb Reconstruction (+8%), with FY 2025 growth of +10%, +6%, and +16%, respectively. The company cited progress in Spine commercial channel optimization and continued adoption of enabling technologies such as 7D FLASH Navigation, and reiterated plans for product rollouts including TRUELOK Elevate, FITBONE nails, and a second-half 2026 full launch of VIRATA. Orthofix guided FY 2026 net sales to USD 850 million to USD 860 million and non-GAAP adjusted EBITDA to USD 95 million to USD 98 million, and said it expects positive FY 2026 free cash flow excluding potential legal settlements.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Orthofix Medical Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260224696551) on February 24, 2026, and is solely responsible for the information contained therein.